We found that EGFR tyrosine kinase inhibitors and the monoclonal humanized anti-EGFR antibody Cetuximab, which are drugs approved for the treatment of several types of cancers, increased the constitutive expression of HBD1 in vitro and ex vivo. The gene discussed is DEFB1; the disease is cancer.